Jatrorrhizine alleviates cytokine storm secondary lung injury via regulating CD39 ‐dominant purinergic braking and downstream NLRP3 inflammasome
Phytotherapy Research · 2025
DOI: 10.1002/ptr.8062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytotherapy Research, 2025. Verfasst von Yuejia Lan und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditi…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Apyrase, Inflammasomes, Acute Lung Injury. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Sichuan, Postdoctoral Science Foundation of China.
Abstract (Originalsprache)
Cytokine storm secondary lung injury (CSSLI) is a form of acute lung injury (ALI) comparable to that caused by sepsis for which there are no effective therapeutic strategies. Coptis chinensis Franch. and Scutellaria baicalensis Georgi. are two botanical medicines that exhibit anti‐inflammatory properties. This study aimed to investigate the underlying therapeutic mechanism of the combination (CCSB) treatment in mice with ALI. A high dosage of lipopolysaccharide (LPS) was administered intraperitoneally to C57BL/6 mice to establish an ALI model. The AMP‐Glo™ assay was applied to screen for the component with the most potent CD39‐promoting enzyme activity from CCSB constituents migrating to the bloodstream. The PMA‐differentiated THP‐1 and RAW264.7 macrophage cell lines were stimulated with LPS and adenosine triphosphate, followed by treatment with Jatrorrhizine (JH). The administration of CCSB demonstrated a notable improvement in lung injury through the modulation of the CD39‐P2X7 purinergic pathway and subsequent regulation of the NLRP3 inflammasome. The restrained CD39 and A2b were reversed by JH, leading to the suppression of the P2X7‐NLRP3 signaling pathway. In addition, the utilization of a CD39 inhibitor (POM‐1) attenuated the inhibitory effect of JH on the NLRP3 signaling pathway. CCSB successfully rescued CSSLI, along with its small‐molecule component JH, which demonstrated the ability to inhibit the NLRP3 signaling pathway and pyroptosis, at least partially through regulating the CD39 enzyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
- Chengdu University of Traditional Chinese Medicine-Affiliated Meishan Hospital/Meishan Hospital of Traditional Chinese Medicine, Meishan, People's Republic of China.
- Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China.
ORCID-Profile: Yuejia Lan, Jiasi Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Sichuan
- Postdoctoral Science Foundation of China
- Xinglin Scholar Research Promotion Project of Chengdu University of TCM
- Natural Science Foundation of Sichuan Province
Zitieren
APA
Lan, Y., Wang, H., Jing, L., Li, R., Sun, J., Meng, X., & Wu, J. (2025). Jatrorrhizine alleviates cytokine storm secondary lung injury via regulating CD39 ‐dominant purinergic braking and downstream NLRP3 inflammasome. Phytotherapy Research. https://doi.org/10.1002/ptr.8062
Vancouver
Lan Y, Wang H, Jing L, Li R, Sun J, Meng X, et al. Jatrorrhizine alleviates cytokine storm secondary lung injury via regulating CD39 ‐dominant purinergic braking and downstream NLRP3 inflammasome. Phytotherapy Research. 2025. doi:10.1002/ptr.8062
BibTeX
@article{Lan2025,
author = {Lan, Yuejia and Wang, Huan and Jing, Lijia and Li, Rui and Sun, Jiayi and Meng, Xianli and Wu, Jiasi},
title = {Jatrorrhizine alleviates cytokine storm secondary lung injury via regulating CD39 ‐dominant purinergic braking and downstream NLRP3 inflammasome},
journal = {Phytotherapy Research},
year = {2025},
doi = {10.1002/ptr.8062}
}
EUVIMED